A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3 - Related Studies

A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3

This study has been completed.

Study NCT00000754. Last updated on July 29, 2008. Information provided by National Institute of Allergy and Infectious Diseases (NIAID)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		HIV Infections

2	Additional conditions recognized in this trial
		Acquired Immunodeficiency Syndrome
		Communicable Diseases
		Infection

3	More general conditions related to this trial
		Immune System Diseases
		Immunologic Deficiency Syndromes
		Lentivirus Infections
		Retroviridae Infections
		RNA Virus Infections
		Sexually Transmitted Diseases
		Sexually Transmitted Diseases, Viral
		Slow Virus Diseases
		Virus Diseases

4	Interventions listed in this trial
		Interferon alfa-2a
		Zidovudine
		Zalcitabine

5	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferon Type I, Recombinant
		Interferon-alpha
		Interferons

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antimetabolites
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Growth Inhibitors
		Growth Substances
		Immunologic Factors
		Molecular Mechanisms of Pharmacological Action
		Nucleic Acid Synthesis Inhibitors
		Pharmacologic Actions
		Physiological Effects of Drugs
		Reverse Transcriptase Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Hoffmann-La Roche
		National Institute of Allergy and Infectious Diseases (NIAID)
		Glaxo Wellcome